Novo Nordisk NVO shares fell roughly 4% in pre-market trading today after U.S. President Donald Trump signaled potential steep price cuts for the company’s blockbuster GLP-1 RA drugs during a White ...

The clinical development plan is a blueprint that brings a new drug discovery from preclinical development to market approval. It helps to regulate the process of drug discovery, ensuring patient ...

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

“The actions outlined today will better position us to drive meaningful earnings growth and further strengthen the company to ...

Glucagon-like peptide agonists (GLP-1s, like Ozempic, Wegovy, and Mounjaro) have been hailed as breakthroughs. From statins to Viagra, occasionally a drug development breakthrough occurs that is ...

AnaptysBio plans to advance rosnilimab for RA, with a program update expected in the first half of 2026. Read why ANAB stock ...

The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

The greater part of third quarter earnings results are in the rearview mirror, though investors this week are looking to ...

Q3 2025 Earnings Call November 13, 2025 9:00 AM ESTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid ...